In patients with atrial fibrillation undergoing PCI, antithrombotic regimens involving a vitamin K antagonist (VKA) plus dual antiplatelet therapy (DAPT) should be avoided, whereas use of a non-VKA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results